Published in Rev Recent Clin Trials on May 01, 2007
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat (2009) 1.47
Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. Expert Opin Investig Drugs (2010) 0.81
Sorafenib in combination with low-dose-homoharringtonine as a salvage therapy in primary refractory FLT3-ITD-positive AML: a case report and review of literature. Int J Clin Exp Med (2015) 0.76
High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in FLT3 internal tandem duplication (ITD) negative patients in adult acute myeloid leukaemia: A prospective pilot study from India. Indian J Med Res (2016) 0.75
Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett (2016) 0.75
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol (2010) 9.01
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet (2011) 4.85
5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci (2011) 4.15
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol (2013) 2.42
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol (2009) 2.02
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood (2014) 1.64
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A (2002) 1.57
DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res (2010) 1.49
The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells. Leuk Lymphoma (2008) 1.44
DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood (2011) 1.40
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica (2012) 1.39
Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res (2011) 1.38
Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits. Genetics (2013) 1.31
Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics (2012) 1.29
High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma. Biochem Biophys Res Commun (2009) 1.23
Epigenetic regulation of hypoxic sensing disrupts cardiorespiratory homeostasis. Proc Natl Acad Sci U S A (2012) 1.13
Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma (2012) 1.13
Aberrant RNA splicing and its functional consequences in cancer cells. Dis Model Mech (2008) 1.12
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma (2009) 0.99
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2008) 0.98
The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cells Mol Dis (2010) 0.98
Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells. Anticancer Drugs (2013) 0.97
Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced lymphomagenesis. Blood (2013) 0.97
Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer (2010) 0.94
The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma (2007) 0.93
A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma (2014) 0.92
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 0.92
Profiles in leukemia. N Engl J Med (2012) 0.92
Identification and molecular characterization of a novel 3′ mutation in RUNX1 in a family with familial platelet disorder. Leuk Lymphoma (2010) 0.91
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol (2011) 0.90
Recognizing familial myeloid leukemia in adults. Ther Adv Hematol (2013) 0.90
Cell characterization using a protein-functionalized pore. Lab Chip (2008) 0.89
Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies. Semin Hematol (2013) 0.88
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leuk Lymphoma (2012) 0.88
Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma. Cancer Res (2012) 0.88
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma (2010) 0.87
New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine. Immunol Rev (2015) 0.87
Alterations of 5-hydroxymethylcytosine in human cancers. Cancers (Basel) (2013) 0.85
The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol Cancer Ther (2014) 0.83
Perspectives and future directions for epigenetics in hematology. Blood (2013) 0.82
Recurrent Systemic Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma Presenting as a Breast Implant-Associated Lesion. Cancer Control (2015) 0.82
Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma (2013) 0.82
Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci (2014) 0.81
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs (2014) 0.80
An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. Onco Targets Ther (2010) 0.80
Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy (2012) 0.79
Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. Int J Gynecol Pathol (2012) 0.76
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma (2012) 0.76
Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood (2012) 0.76
Corrigendum: TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiating colonocytes and colon cancer. Sci Rep (2016) 0.76
Getting to the root of the stem cell in mutated chronic myeloid leukemia. Leuk Lymphoma (2010) 0.75
Characterization of CpG sites that escape methylation on the inactive human X-chromosome. Epigenetics (2015) 0.75
Node-pore sensing enables label-free surface-marker profiling of single cells. Anal Chem (2015) 0.75
An update on current and prospective immunotherapies for chronic lymphocytic leukemia. Immunotherapy (2015) 0.75